Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization. 2013

Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
Children's Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

OBJECTIVE To assess the strength of thrombin formation and determine the effects of unfractionated heparin (UFH) in children during cardiac catheterization. BACKGROUND UFH reduces the thrombotic risk related to catheterization but the effects of UFH on the coagulation system in children, and proper monitoring of UFH remain unclear. METHODS We studied 42 patients aged 3-12 years undergoing catheterization. Twenty-seven received UFH (group A) and 15 patients did not (group B). Anticoagulation was assessed by measurements of plasma prothrombin fragment F1 + 2, thrombin-antithrombin (TAT) complexes, D-dimer, activated partial thromboplastin time (APTT), anti-FXa, and prothrombinase-induced clotting time (PiCT). RESULTS Markers of thrombin generation remained low during catheterization in group A. In group B, both F1 + 2 and TAT had increased significantly (P < 0.05) by the end of the procedure versus baseline and versus respective levels in group A. In group A, 15 min after heparinization, APTT was over 180 sec (in all patients), anti-FXa 1.4 U/ml (1.1-2.4 U/ml) and PiCT 1.5 U/ml (1.3-2.4 U/ml). Anti-FXa and PiCT were correlated (R = 0.84, P < 0.0001). CONCLUSIONS Thrombin generation was enhanced in patients who did not receive UFH, which may increase the risk of thrombotic complications. In group A, routine heparinization seemed excessive by all monitoring methods. UFH prevented an increase in prothrombin to thrombin conversion, resulting in unaltered fibrin formation. The current UFH protocol seemed to have no effect on postprocedural activation of coagulation. Further studies are needed to clarify adequate heparin dosing for children during cardiac catheterization to prevent thrombotic complications without predisposing the patient to bleeding complications.

UI MeSH Term Description Entries
D008297 Male Males
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
January 2003, Thrombosis research,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
May 2010, Journal of thrombosis and thrombolysis,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
January 1995, Cardiology,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
October 2017, The Canadian journal of cardiology,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
December 1988, The American journal of cardiology,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
November 2020, Scientific reports,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
March 2014, The Cochrane database of systematic reviews,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
February 2020, The Cochrane database of systematic reviews,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
October 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Dawei Chen, and Satu Långström, and Jari Petäjä, and Markku Heikinheimo, and Jaana Pihkala
January 1993, Seminars in thrombosis and hemostasis,
Copied contents to your clipboard!